큐라티스
Financials
Valuation Metrics
큐라티스's Market Cap is ₩455B. At end of 2025 it was ₩1457B. Ranked #1772 of 2,405 in KR market (top 74%), #1081 of 1,627 on KOSDAQ (top 66%), #189 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 45.54B KRW | KR#1,772/2,405 Sec#189/231 |
| Revenue | 1.10B KRW | KR#2,370/2,405 Sec#217/231 |
| Net Income | -23.90B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 58.09B KRW | KR#2,119/2,405 Sec#187/231 |
| Net Assets | 47.28B KRW | KR#1,939/2,405 Sec#162/231 |
| Employees | 72 | KR#1,856/2,405 Sec#160/231 |
| Value | ||
| P/B | 0.96x | KR#1,507/2,405 Sec#93/231 |
| P/S | 41.55x | KR#2,354/2,405 Sec#196/231 |
| FCF Yield | -33.55% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -50.54% | KR#2,263/2,405 Sec#196/231 |
| ROA | -41.13% | KR#2,333/2,405 Sec#211/231 |
| Op. Margin | -892.81% | KR#2,362/2,405 Sec#213/231 |
| Revenue Growth | -41.14% | KR#2,251/2,405 Sec#201/231 |
| Financial Health | ||
| Debt Ratio | 22.87% | KR#429/2,405 Sec#52/231 |
| Total Debt | 9.43B KRW | KR#1,635/2,405 Sec#148/231 |
| FCF | -15.28B KRW | KR#1,819/2,405 Sec#169/231 |
| Cash | 11.97B KRW | KR#1,587/2,405 Sec#134/231 |
| Current Ratio | 1.29x | KR#1,396/2,405 Sec#146/231 |
| Performance | ||
| 1Y Return | -54.35% | KR#2,036/2,405 Sec#178/231 |
| 1M Return | -7.31% | KR#922/2,405 Sec#86/231 |
| From 52W High | -72.64% | KR#2,136/2,405 Sec#188/231 |
| 1Y MDD | -84.62% | KR#2,342/2,405 Sec#220/231 |
| Trading | ||
| Volume | 8,320 shares | KR#1,921/2,405 Sec#193/231 |
| Trading Value | 29.0M KRW | KR#1,970/2,405 Sec#205/231 |
| Foreign Own. | 0.83% | KR#2,080/2,405 Sec#204/231 |
| Per Share | ||
| EPS | -1,863 KRW | KR—/2,405 Sec—/231 |
| BPS | 3,686 KRW | KR#1,743/2,405 Sec#128/231 |
Company Info
Established in 2016, this company possesses vaccine development platform technology and was listed on KOSDAQ in 2023. It is developing preventive vaccines for adult and adolescent tuberculosis, schistosomiasis, and next-generation mRNA COVID-19, operating manufacturing facilities and research laboratories that meet cGMP, EU-GMP, and KGMP standards. Utilizing its vaccine development platform technology, the company conducts the entire new drug development process and offers services and consulting to bio new drug development clients. Curatis, established in 2016, is headquartered in Chungcheongbuk Province, Cheongju City.